Black checkmark with a sparkle and a curved line underneath on a white background.
Company

BIO-TECHNE Corp

Ticker
TECH
Sector
Industry
Report date
November 13, 2026
Valye AI Score

97

Very high visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings and revenues surpassing expectations, progress on the Merck KGaA merger deal with shareholder approval, a decline in Q1 profit, and declaration of a quarterly dividend.

Recent developments:
  • BIO-TECHNE Corp reported Q1 earnings and revenues exceeding expectations, alongside advancement of the Merck KGaA merger deal [N3].
  • Shareholders approved the Merck KGaA acquisition plan, signaling support for strategic growth initiatives [N3].
  • The company declared a quarterly dividend of $0.08 per share, reflecting ongoing shareholder returns [N6].
  • Q1 profit declined compared to prior periods, indicating some profitability pressures [N5].
Overview

BIO-TECHNE Corp is a publicly traded company listed on NASDAQ under the ticker TECH. The company operates in the life sciences sector, with a focus on providing products and services related to bioengineering, diagnostics, and scientific research. The company maintains a diversified product portfolio and operates globally, with nearly half of its business derived from international markets. The Board of Directors includes members with extensive experience in scientific, financial, and operational domains, supporting strategic growth and risk management. Recent filings indicate a solid financial position with positive net income and strong liquidity ratios as of September 30, 2026. The company is actively pursuing merger and acquisition strategies, including a merger deal with Merck KGaA that has received shareholder approval. Dividend payments continue as part of shareholder returns.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. BIO-TECHNE Corp reported revenues of approximately $299.7 million and net income of $28.3 million for the quarter ended September 30, 2026, with a strong liquidity position reflected by a current ratio of 2.28 and cash ratio of 1.06. The company is engaged in merger activities with Merck KGaA, with shareholder approval obtained. Recent news also notes a quarterly dividend declaration and a decline in Q1 profit. The Board comprises experienced directors with expertise in finance, life sciences, and operations [S1][S2][N3][N5][N6].

Scenarios for TECH

Bull case model:

The company demonstrates strong operational execution with recent quarterly revenues and earnings showing positive results. The advancement of the merger deal with Merck KGaA and shareholder approval indicates strategic growth initiatives are progressing. The company maintains a healthy liquidity position, supporting ongoing investments and operational needs. Experienced leadership and a knowledgeable board provide governance and oversight conducive to navigating industry complexities and capitalizing on growth opportunities. Continued dividend payments reflect a commitment to shareholder returns.

Bear case model:

The company reported a decline in Q1 profit, indicating potential pressures on profitability. Merger and acquisition activities carry integration and execution risks that could impact operational focus and financial performance. The life sciences tools and diagnostics industry is complex and competitive, with regulatory and market risks that could affect product acceptance and revenue growth. Operational challenges related to manufacturing and supply chain complexities may also pose risks. Changes in global market conditions and currency fluctuations could impact international business segments.

Moat:

BIO-TECHNE Corp's moat is supported by its specialized expertise in life science tools and diagnostics, a broad and complex product portfolio, and a global operational footprint. The company's board and management team bring deep industry knowledge and strategic leadership, particularly in mergers and acquisitions, which are key to expanding product offerings and revenue streams. The company's ability to navigate regulatory complexities, maintain operational efficiencies, and leverage scientific innovation contributes to its competitive positioning. Its established relationships with customers and ongoing investments in technology and bioengineering further reinforce its market presence.

Risks overview
Risks summary
The primary risks involve successful execution of merger activities, managing profitability pressures, and navigating the complex regulatory and operational environment of the life sciences industry.
Risks details:

• Merger and Acquisition Risks: Integration challenges and execution risks related to the Merck KGaA merger deal could affect operational performance and financial results.
• Profitability Pressures: Recent decline in Q1 profit suggests potential margin pressures or cost challenges that may impact future earnings.
• Industry and Regulatory Complexity: Operating in the life sciences tools and diagnostics sector involves navigating complex regulatory environments and competitive pressures.
• Operational and Supply Chain Risks: Manufacturing and supply chain complexities could disrupt product availability and increase costs.
• Global Market Risks: Significant international business exposes the company to currency fluctuations and geopolitical uncertainties.

FINAL FORECAST FOR TECH

Final take one line
BIO-TECHNE Corp exhibits very high visibility with detailed SEC filings, active merger progress, and recent financial disclosures indicating solid liquidity and operational execution.
Final take 12 to 24 month view

Business trends: The company is actively pursuing strategic growth through mergers and acquisitions, maintaining dividend payments, and operating with strong liquidity and revenue generation.
Execution milestones: Advancement and shareholder approval of the Merck KGaA merger deal, quarterly earnings and revenues surpassing prior periods, and ongoing dividend declarations.
Key risks: Execution risks related to merger integration, profitability pressures, regulatory and operational complexities in the life sciences sector, and exposure to global market uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

97
LLM visibility overview
LLM Visibility known facts
  • BIO-TECHNE Corp is a publicly traded company on NASDAQ under the ticker TECH [S1].
  • As of September 30, 2026, the company reported cash and cash equivalents of $350.0 million and current assets of $824.8 million, with current liabilities of $361.3 million, resulting in a current ratio of 2.28 and a cash ratio of 1.06 [S2].
  • For the quarter ended September 30, 2026, BIO-TECHNE reported revenues of approximately $299.7 million and net income of $28.3 million, with basic and diluted EPS of $0.18 per share [S2].
  • The company filed an amended 10-K/A for fiscal year ended June 30, 2026, and a 10-Q/A for the quarter ended September 30, 2026, indicating compliance with SEC reporting requirements and detailed disclosures on governance and financials [S1][S2].
  • As of October 9, 2026, BIO-TECHNE had approximately 157.1 million shares outstanding [S1].
  • The Board of Directors includes experienced executives with backgrounds in finance, operations, life sciences, and technology, including an independent chair and members with expertise in scientific research, corporate finance, and risk management [S1].
  • Recent news highlights include Q1 earnings and revenues surpassing expectations and advancement of a merger deal with Merck KGaA, shareholder approval of the acquisition plan, and declaration of a quarterly dividend of $0.08 per share [N3][N6][N3][N5].
  • The company reported a decline in Q1 profit but continues to maintain dividend payments and strategic merger activities [N5][N6].
  • Liquidity ratios and financial figures are derived from the latest SEC filings and are provided for informational purposes only — not financial advice [S2].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-10-28 | 10-K/A
  • S2 | 2026-11-12 | 10-Q/A
Sources - News headlines
  • N1 | 2026-11-12 | www.nasdaq.com | CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/cormedix-crmd-reports-q3-loss-tops-revenue-estimates
  • N2 | 2026-11-10 | www.nasdaq.com | Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/humacyte-inc-huma-reports-q3-loss-tops-revenue-estimates
  • N3 | 2026-11-09 | www.nasdaq.com | TECH Q1 Earnings & Revenues Beat, Merck KGaA Merger Deal Advances | https://www.nasdaq.com/articles/tech-q1-earnings-revenues-beat-merck-kgaa-merger-deal-advances
  • N4 | 2026-11-09 | www.nasdaq.com | Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/roivant-sciences-ltd-roiv-reports-q2-loss-tops-revenue-estimates
  • N5 | 2026-11-09 | www.nasdaq.com | Bio-Techne Q1 Profit Down | https://www.nasdaq.com/articles/bio-techne-q1-profit-down
  • N6 | 2026-11-04 | www.nasdaq.com | Bio-Techne Corporation Declares Quarterly Dividend of $0.08 Per Share | https://www.nasdaq.com/articles/bio-techne-corporation-declares-quarterly-dividend-008-share
  • N7 | 2026-11-03 | www.nasdaq.com | Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/rhythm-pharmaceuticals-inc-rytm-reports-q3-loss-beats-revenue-estimates
  • N8 | 2026-11-02 | www.nasdaq.com | CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/crispr-therapeutics-ag-crsp-reports-q3-loss-tops-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine